Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – FBR & Co issued their Q3 2017 EPS estimates for shares of Jazz Pharmaceuticals PLC in a report issued on Wednesday. FBR & Co analyst D. Buck expects that the specialty pharmaceutical company will post earnings of $2.52 per share for the quarter. FBR & Co currently has a “Buy” rating and a $206.00 target price on the stock. FBR & Co also issued estimates for Jazz Pharmaceuticals PLC’s FY2017 earnings at $9.66 EPS, FY2018 earnings at $11.55 EPS and FY2019 earnings at $13.77 EPS.

Other analysts have also recently issued research reports about the stock. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Deutsche Bank AG reiterated a “buy” rating and set a $176.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, July 4th. Piper Jaffray Companies set a $182.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a report on Friday, July 14th. Cowen and Company reiterated a “buy” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Friday, July 14th. Finally, Mizuho lowered shares of Jazz Pharmaceuticals PLC from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $162.00 to $150.00 in a report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $180.88.

ILLEGAL ACTIVITY WARNING: “Research Analysts Issue Forecasts for Jazz Pharmaceuticals PLC’s Q3 2017 Earnings (JAZZ)” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/23/research-analysts-issue-forecasts-for-jazz-pharmaceuticals-plcs-q3-2017-earnings-jazz.html.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 144.05 on Monday. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75. The firm has a market cap of $8.65 billion, a P/E ratio of 22.19 and a beta of 1.05. The firm has a 50 day moving average price of $147.72 and a 200 day moving average price of $151.35.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The firm had revenue of $394.39 million during the quarter, compared to analyst estimates of $410.83 million. During the same period in the prior year, the business earned $2.67 EPS. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year.

In other news, SVP Paul Treacy sold 1,304 shares of the stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $143.32, for a total transaction of $186,889.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total transaction of $153,520.00. The disclosure for this sale can be found here. Insiders have sold a total of 4,517 shares of company stock valued at $665,623 over the last three months. Insiders own 4.30% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in JAZZ. BlackRock Inc. grew its position in shares of Jazz Pharmaceuticals PLC by 3,163.9% during the 1st quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock valued at $466,615,000 after acquiring an additional 3,116,652 shares during the period. Janus Henderson Group PLC grew its position in shares of Jazz Pharmaceuticals PLC by 11,990.7% during the 2nd quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock valued at $135,894,000 after acquiring an additional 866,691 shares during the period. FMR LLC grew its position in shares of Jazz Pharmaceuticals PLC by 11.4% during the 2nd quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after acquiring an additional 849,348 shares during the period. JPMorgan Chase & Co. grew its position in shares of Jazz Pharmaceuticals PLC by 41.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after acquiring an additional 410,031 shares during the period. Finally, American Century Companies Inc. boosted its holdings in Jazz Pharmaceuticals PLC by 133.2% in the 2nd quarter. American Century Companies Inc. now owns 549,900 shares of the specialty pharmaceutical company’s stock worth $85,509,000 after buying an additional 314,094 shares during the period. 87.82% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Earnings History and Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.